<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119335">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01892670</url>
  </required_header>
  <id_info>
    <org_study_id>2012/2279</org_study_id>
    <nct_id>NCT01892670</nct_id>
  </id_info>
  <brief_title>Storage Temperature and Quality of Leucoreduced Whole Blood</brief_title>
  <acronym>BFF</acronym>
  <official_title>Storage Temperature and Quality of Leucoreduced Whole Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Armed Forces Medical Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <authority>Norway: Regional Ethics Commitee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a combat situation the need for safe and high-quality blood products is increasing. Whole
      blood is used in many trauma situations, but we wish to investigate whether there is an even
      better whole blood product.

      The purpose of this study is to examine the quality of leucoreduced, cold-stored whole
      blood. We also wish to examine the effects of filtration of whole blood without a 1-2 hour
      holding-time (warm-filtration) and the effects of forced filtration.

      Analyses are performed with a main focus to investigate function and quality of red blood
      cells and platelets.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Platelet function</measure>
    <time_frame>After 10 days of cold-storage</time_frame>
    <safety_issue>No</safety_issue>
    <description>Platelet function is assessed by various parameters, such as thrombelastography (TEG), Multiplate and flow cytometry (Lactadherin, Calcein violet AM, ++).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukocyte count</measure>
    <time_frame>After leukocyte filtration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Filtered whole blood should have a concentration less than 1*10^6 cells/L to avoid transfusion reactions.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Whole Blood</condition>
  <condition>Platelet Function</condition>
  <condition>Hemolysis</condition>
  <condition>Filtration</condition>
  <arm_group>
    <arm_group_label>Filtered whole blood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leukocyte-reduced whole blood, 2 hours holding-time after collection. Gravitational filtration.
Device: Terumo IMUFLEX WB-SP collection bag system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unfiltered whole blood</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-leukocyte-reduced whole blood, 2 hours holding-time after collection.
Device: Terumo IMUFLEX WB-SP collection bag system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warm-filtered whole blood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leukocyte-reduced whole blood, no holding-time after collection. Gravitational filtration.
Device: Terumo IMUFLEX WB-SP collection bag system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Forced warm-filtration of whole bood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leukocyte-reduced whole blood, no holding-time after collection. Forced filtration.
Device: Terumo IMUFLEX WB-SP collection bag system</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Donation of 1 whole blood unit</intervention_name>
    <description>Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.</description>
    <arm_group_label>Filtered whole blood</arm_group_label>
    <arm_group_label>Unfiltered whole blood</arm_group_label>
    <arm_group_label>Warm-filtered whole blood</arm_group_label>
    <arm_group_label>Forced warm-filtration of whole bood</arm_group_label>
    <other_name>Terumo IMUFLEX WB-SP collection bag system.</other_name>
    <other_name>(IMUFLEX® WB-SP features an in-line, saving-platelets filter that provides a way to</other_name>
    <other_name>produce a leukocyte-reduced platelet concentrate — from whole blood.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer

          -  Age between 18 and 70

          -  Negative pregnancy test (women in fertile age)

          -  Blood pressure range: (160-100)/(100-40)

          -  Pulse range: 40-100

        Exclusion Criteria:

          -  Usage of platelet-influencing medication

          -  Mild flu or more severe illnesses

          -  Open wound

          -  Pregnancy or trying to get pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geir Strandenes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital and Norwegian Naval Special Operation Commando</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital, Dept of Immunology and Transfusion Medicine</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://rdcr.org/</url>
    <description>THOR: Trauma Hemostasis and Oxygenation Research Network. Main objective: To reduce the risk of death from traumatic hemorrhagic shock prior to admission at a trauma center</description>
  </link>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 12, 2013</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood</keyword>
  <keyword>Whole blood</keyword>
  <keyword>Cold-storage</keyword>
  <keyword>Filtration</keyword>
  <keyword>Transfusion</keyword>
  <keyword>Platelet-function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
